France· FR:63485353
GLIVEC 400 mg, comprimé pelliculé
A medicinal product containing imatinib (mésilate d'), registered in France by NOVARTIS EUROPHARM (IRLANDE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- IMATINIB (MÉSILATE D')
- Manufacturer
- NOVARTIS EUROPHARM (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
2 priced- cip133400936224988plaquette(s) thermoformée(s) PVDC aluminium de 30 comprimé(s)EUR 609.64
- cip133400949501595plaquette(s) thermoformée(s) PVDC aluminium de 30 comprimé(s) (Distributeur Parallèle : Abacus Medicine A/S)EUR 609.64
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Imatinib (mésilate d') in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaGLIVECNovartis Europharm Limited, Dublin
- United Statesimatinib mesylateSun Pharmaceutical Industries, Inc.
- NetherlandsBimatix 400 mg filmomhulde tablettenStada Arzneimittel AG
- BelgiumGlivec 400 mgNovartis Europharm
- FinlandBimatixSTADA Arzneimittel AG
- SwitzerlandGlivec
- SpainGLIVEC 400 mg COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- SwedenBimatix 400 mg Filmdragerad tablettSTADA Arzneimittel AG
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Imagerolan, Imatinib 1a Pharma
- Belgium · Imatinib Eg, Imatinib Grindeks
- Bulgaria · Иматиниб Тева Фарма, Меаксин
- Cyprus · Imarem, Imatinib Koanaa 100 Mg
- Czechia · Imanivec, Imatinib Grindeks
- Germany · Imanivec, Imatinib 1 A Pharma
- Denmark · Bimatix, Imatinib "sandoz"
- Estonia · Glipox, Imatinib Grindeks
- Spain · Imatinib Cipla, Imatinib Farmalider
- Finland · Bimatix, Imatinib Hexal
- United Kingdom (Northern Ireland) · Imatinib, Imatinib Amarox
- Greece · Imatek, Imatinib Aenorasis
- Croatia · Imakrebin, Meaxin
- Hungary · Imaniver, Imatinib 1 A Pharma
- Ireland · Imatinib Krka D.D., Imatinib Rowex
- Iceland · Bimatix, Glivec
- Italy · Imanivec, Imatinib Dr. Reddy’s
- Liechtenstein · Glivec, Imatinib Accord
- Lithuania · Glipox, Imatinib Grindeks
- Luxembourg · Imatinib, Imatinib Eg
- Latvia · Imatinib Grindeks, Imatinib Inteli
- Malta · Imatinib Tad, Nibix
- Netherlands · Bimatix, Imakrebin
- Norway · Bimatix, Glivec
- Poland · Imatenil, Meaxin
- Portugal · Imatinib Aurobindo, Imatinib Aurovitas
- Romania · Imakrebin, Imatinib Grindeks
- Sweden · Bimatix, Imatinib Amarox
- Slovenia · Meaxin
- Slovakia · Imatinib Glenmark, Imatinib Grindeks
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5741e278-8dd3-4c8a-aa27-b73f1c19b0a9 GET /v1/drugs/5741e278-8dd3-4c8a-aa27-b73f1c19b0a9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63485353",
"date_amm": "2003-11-11",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/01/198",
"substance": "IMATINIB (MÉSILATE D')",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about imatinib (mésilate d').
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.